# Patent

## Title
4-aminoquinazoline derivatives and uses thereof

## Abstract

The present invention provides a 4-aminoquinazoline derivative having the chemical structure of the following formula, and the use thereof. It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention not only has distinct inhibitory effect on histone deacetylases, but also has stronger differentiation induction and anti-proliferative activities for certain tumor cells. It can be used in the treatment of cancers and diseases related to cell differentiation and proliferation. Excellent efficacy is observed especially for leukemia and a solid tumor. As demonstrated by the animal test, the compound or a salt thereof according to the present invention is less toxic.

## Background
CROSS REFERENCE TO RELATED APPLICATION
The present application is the U.S. national stage of International Application PCT/CN2012/075297, filed May 10, 2012, which international application was published on Nov. 22, 2012, as International Publication No. WO20121155806. The International Application claims priority to Chinese Patent Application No. 201110124632.5, filed May 13, 2011, the contents of which are incorporated herein by reference in their entireties.
TECHNICAL FIELD
The present invention relates to a method for synthesizing 4-aminoquinazoline derivatives capable of inhibiting histone deacetylases, and the use thereof for treating malignant tumors and diseases related to cell differentiation and proliferation.
BACKGROUND
Acetylation and deacetylation of histones in the chromatin is a key step in regulating the gene expression, whereas abnormality in gene expression constitutes the molecular biological basis for the occurrence of tumors and some hereditary and metabolic diseases. The acetylation degree of histones is co-regulated by histone acetylases (HATs) and histone deacetylases (HDACs). Overexpression of HDACs and the recruitment thereof by transcription factors would cause abnormal inhibition of specific genes, leading to tumors and other diseases (Grunstein, M., 1997, Nature, 389:349-352). The HDAC activity is reported to be related to the occurrence of cancers, immunological diseases, and some mental and cardiovascular diseases (Ruijter, A-J-M., 2003, Biochem. J., 370:737-749; Grignani, F., 1998, Nature, 391:815-818; Lin, R-J, 1998, 391:811-814; Marks, P-A., 2001, Nature Reviews Cancer, 1:194).
It is experimentally demonstrated that the inhibitor of HDACs can increase the level of acetylation of histones in the chromatin, accordingly causing the activation and expression of specific genes and in turn the terminal differentiation of cells or the apoptosis of cancer cells. Preliminary clinical research has shown that it is safe for a human to achieve a high acetylation level of histones by inhibiting the HDAC activity. Therefore, HDACs are of the newest and hottest targets in the current research and development area for chemotherapeutic drugs.
HDAC is an enzyme superfamily with its members known to occur in four classes comprising 18 different subtypes, wherein Class I comprises four subtypes, namely HDAC1, 2, 3, and 8; Class II comprises six subtypes, namely HDAC4, 5, 6, 7, 9, and 10 (wherein HDAC4, 5, 7, and 9 belong to Class IIa, and HDAC6 and 10 belong to Class IIb); Class IV only comprises one subtype, HDAC11 which shares certain homology with the previous two classes; Class III comprises seven subtypes in total including Sirt1-7 which do not share any structural homology with the previous three classes. At present, HDAC subtypes in Class I and Class II are relatively better studied, but not much is known about Class III and Class IV of HDACs. HDAC Class I proteins mainly localize in the nucleus and are expressed in cells of multiple tissues. HDAC Class II proteins mainly localize in the cytoplasm (or shuttle between the nucleus and the cytoplasm) and are only expressed in cells of some kinds of tissues. Results from research using small interfering RNA technique and animal gene knockout technique have shown comprehensively that some HDAC subtypes from Class I and Class IIa could be the target relevant to an antitumor effect, wherein inhibiting HDAC1, 2 and 3 can result in inhibition of cell proliferation; inhibiting HDAC4 can affect the repair processes of DNA damage; and inhibiting HDAC7 can induce apoptosis of thymocytes.
Research in recent years has fully demonstrated that the overexpression or abnormal activities of HDACs play an important role in the occurrence and development of leukemia and a solid tumor. It is shown that significant in vivo and in vitro antitumor effects can be achieved by inhibiting the HDAC functional activity. HDAC inhibitors currently under investigation in clinical trials can be categorized into four groups based on their chemical structures, namely:
(1) hydroxamic acids, e.g. trichostatin (TSA), and suberolanilide hydroxamic acid (SAHA);
(2) cyclic tetrapeptides, e.g. Apicidin;
(3) short-chain or aromatic fatty acids, e.g. sodium butyrate; and
(4) benzamides, e.g. MS-275.
The first two groups of compounds are non-selective HDAC inhibitors and inhibit all HDAC subtypes in Class I and Class II. Short-chain or aromatic fatty acids generally have weaker inhibition activities and need to be tested in combination with other medicaments to provide stronger effects. Benzamides, however, are selective with targeting effects and mainly inhibit Class I HDACs (including HDAC subtypes 1, 2 and 3 but not HDAC8) and part of Class IIa HDACs and have no inhibitory effect on Class IIb HDACs. At present, antitumor drugs targeting HDACs are being investigated worldwide. SAHA (Trade name Zolinza) developed by Merk Company has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) and launched at the end of 2006. This not only indicates the end of the confirmatory research phase for the concept of using HDAC as a novel drug target, but also implies a broad prospect of developing HDAC inhibitors as novel antitumor drugs. Meanwhile, studies on the mechanisms underlying the antitumor effect of HDAC inhibitors are gradually going deeper and encompass multiple aspects related to the tumor formation and development such as induction of tumor cell apoptosis, inhibition of tumor cell cycle, induction of tumor cell differentiation, inhibition of angiogenesis, inhibition of tumor metastasis, and regulation of the immune system function etc.
Due to the structure similarity of the HDAC subtypes, most of the present HDAC inhibitors are not selective towards these subtypes and typically inhibit multiple subtypes at the same time, causing certain side effects and thus affecting the druggability of the inhibitors. Consequently, research focus and technical difficulty in the prior art of this area is to obtain a novel and effective anti-malignant tumor agent with low adverse side effects and high safety by designing and synthesizing highly selective HDAC inhibitors, especially the benzamides.
SUMMARY OF THE INVENTION
One of the technical problems to be solved by the present invention is to disclose a class of 4-aminoquinazoline derivatives to meet the need in the clinical application;
Another technical problem to be solved by the present invention is to disclose the use of the 4-aminoquinazoline derivatives in the preparation of a medicament for treating malignant tumors and diseases related to cell differentiation and proliferation.
The 4-aminoquinazoline derivative in accordance with the present invention is a compound having the chemical structure of the following formula or a salt thereof:




wherein
R1, R2, R3 and R4 each independently represent hydrogen, halogen, amino, nitro, hydroxyamino, carboxyl, C1-C4 alkoxycarbonyl, C1-C4 aminoalkyl, C1-C4 aminoalkyl, C1-C4 alkylamino, C1-C4 alkyl, C1-C4 amido, (E)-4-(dimethylamino)-2-butanamido, alkoxy, guanidyl, carbamido, trifluoromethyl, C1-C4 sulfonyl, aryl sulfonyl, substituted phenyl, phenyl, heterocyclyl or substituted heterocyclyl;
Y is N or C;
X1 is hydrogen, halogen, substituted phenyl, phenyl, heterocyclyl or substituted heterocyclyl;
m=0 or 1;
when R3, R4 and R5 are all hydrogen, then Y is C, and m=1;
when X1 is hydrogen or F, Y is C, and m=1, then R1 and R2 are not both methoxy;
the substituent on the substituted phenyl or substituted heterocyclyl is halogen, amino, hydroxy, nitro, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 aminoalkyl, C1-C4 alkylamino, C1-C4 sulfonyl, C2-C4 acyl, C2-C4 amido, C1-C4 thioalkyl, trifluoromethyl, C1-C4 carboxyl, C1-C4 alkoxycarbonyl, phenyl or heterocyclyl;
the substituted phenyl is a benzene ring with 1 to 4 substituents, wherein the substituent is halogen, hydroxy, nitro, cyano, alkoxy, C1-C4 alkyl or amino group;
the heterocyclyl is a saturated or unsaturated five- or six-membered ring containing one or more hetero atoms selected from the group consisting of N, O and S;
the halogen is F, Cl, Br or I;
preferably, the C1-C4 alkyl represented by R1, R2, R3 and R4 refers to a saturated hydrocarbon chain that is branched, unbranched, or cyclic and contains the specified number of carbon atoms, preferably methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl or cyclobutyl;
preferably, the alkoxy represented by R1, R2, R3 and R4 is C1-C4 alkoxy, substituted benzyloxy, pyrrolidin-1-yl-(C2-C4)alkoxy, morpholin-1-yl-(C2-C4)alkoxy, piperazin-1-yl-(C2-C4)alkoxy, N-methyl piperazin-1-yl-(C2-C4)alkoxy or piperidin-1-yl-(C2-C4)alkoxy;
said amino means —NH2;
preferably, the C1-C4 aminoalkyl represented by R1, R2, R3 and R4 is preferably aminoethyl, 1-aminopropyl or 2-aminopropyl;
preferably, the C1-C4 alkylamino represented by R1, R2, R3 and R4 is preferably N-methylamino, N-ethylamino or N-isopropylamino;
said amido refers to —C(O)NH—, wherein “C1-C4 amido” is a “C1-C4 alkyl” linked to an “amido”, preferably acetamido (CH3C(O)NH—), propionamido (CH3CH2C(O)NH—), butanamido or isobutanamido;
said sulfonyl refers to —SO2—; wherein “C1-C4 sulfonyl” means a “C1-C4 alkyl” linked to a “sulfonyl”, preferably methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, or sec-butylsulfonyl;
said salt is a hydrochloride, hydrobromide, sulfate, acetate, lactate, tartrate, tannate, citrate, trifluoroacetate, malate, maleate, succinate, tosylate or mesylate;
said salt contains no crystal water, or one or more molecules of crystal water, preferably 0.5-3.0 molecules of crystal water.
Preferable compounds comprise:

    V-1 N-(2-aminophenyl)-4-(quinazoline-4-amino)benzamide,
    V-2 N-(2-amino-4-pyridyl)-4-(quinazoline-4-amino)benzamide,
    V-3 N-(2-amino-5-fluorophenyl)-4-(quinazoline-4-amino)benzamide,
    V-4 N-(2-amino-4-pyridyl)-4-(6,7-dimethoxyquinazoline-4-amino)benzamide,
    V-5 N-(2-aminophenyl)-4-(6-methoxyquinazoline-4-amino)benzamide,
    V-6 N-(2-amino-5-fluorophenyl)-4-(6-methoxyquinazoline-4-amino)benzamide,
    V-7 N-(2-aminophenyl)-4-(5-methoxyquinazoline-4-amino)benzamide,
    V-8 N-(2-amino-4-pyridyl)-4-(5-methoxyquinazoline-4-amino)benzamide,
    V-9 N-(2-aminophenyl)-4-(8-methoxyquinazoline-4-amino)benzamide,
    V-10 N-(2-amino-5-fluorophenyl)-4-(8-methoxyquinazoline-4-amino)benzamide,
    V-11 N-(2-aminophenyl)-4-(6-nitroquinazoline-4-amino)benzamide,
    V-12 N-(2-aminophenyl)-4-(6-fluoroquinazoline-4-amino)benzamide,
    V-13 N-(2-aminophenyl)-4-(7-fluoroquinazoline-4-amino)benzamide,
    V-14 N-(2-amino-5-fluorophenyl)-4-(8-fluoroquinazoline-4-amino)benzamide,
    V-15 N-(2-aminophenyl)-4-(6,7-dimethoxyethoxyquinazoline-4-amino)benzamide,
    V-16 N-(2-amino-4-pyridyl)-4-(6,7-dimethoxyethoxyquinazoline-4-amino)benzamide,
    V-17 N-(2-aminophenyl)-4-[7-methoxy-6-(3-morpholinylpropoxy)quinazoline-4-amino]benzamide,
    V-18 N-(2-amino-5-fluorophenyl)-4-[7-methoxy-6-(3-morpholinyl propoxy)quinazoline-4-amino]benzamide,
    V-19 N-(2-aminophenyl)-4-[6-(5-((2-(methylsulfonyl)ethylamino)methyl)furyl)quinazoline-4-amino]benzamide,
    V-20 N-(2-amino-5-fluorophenyl)-4-[6-(5-((2-(methylsulfonyl)ethyl amino)methyl)furyl)quinazoline-4-amino]benzamide,
    V-21 N-(2-aminophenyl)-4-(6-acetamidoquinazoline-4-amino)benzamide.
    V-22 N-(2-aminophenyl)-4-(6-methoxycarbonylmethyl quinazoline-4-amino)benzamide,
    V-23 N-[2-amino-5-(2-thienyl)phenyl]-4-(6,7-dimethoxyquinazoline-4-amino)benzamide,
    V-24 N-[2-amino-5-(phenyl)phenyl]-4-(6,7-dimethoxyquinazoline-4-amino)benzamide,
    V-25 NV-[2-amino-5-(2-furyl)phenyl]-4-(6,7-dimethoxyquinazoline-amino)benzamide,
    V-26 N-(2-amino-4-pyridyl)-4-[(quinazoline-4-amino)methyl]benzamide,
    V-27 N-(2-aminophenyl)-4-[(quinazoline-4-amino)methyl]benzamide,
    V-28 N-[2-amino-5-(2-thienyl)phenyl]-4-[(quinazoline-4-amino)methyl]benzamide,
    V-29 N-(2-amino-5-fluorophenyl)-4-[(quinazoline-4-amino)methyl]benzamide,
    V-30 N-(2-amino-4-pyridyl)-4-[(6,7-dimethoxyquinazoline-4-amino)methyl]benzamide,
    V-31 N-[2-amino-5-(2-thienyl)phenyl]-4-[(6,7-dimethoxyquinazoline-4-amino)methyl]benzamide,
    V-32 N-(2-aminophenyl)-4-[(7-methoxyquinazoline-4-amino)methyl]benzamide,
    V-33 N-(2-aminophenyl)-4-[(6-methoxyquinazoline-4-amino)methyl]benzamide,
    V-34 N-(2-aminophenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide,
    V-35 N-(2-amino-5-fluorophenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide,
    V-36 N-(2-amino-5-(phenyl)phenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide,
    V-37 N-(2-aminophenyl)-4-[(6-nitroquinazoline-4-amino)methyl]benzamide,
    V-38 N-(2-aminophenyl)-4-[(6,7-dimethoxyethoxyquinazoline-4-amino)methyl]benzamide,
    V-39 N-(2-amino-4-pyridyl)-4-[(6,7-dimethoxyethoxyquinazoline-4-amino)methyl]benzamide,
    V-40 N-(2-amino-5-fluorophenyl)-4-[(6,7-dimethoxyethoxy quinazoline-4-amino)methyl]benzamide,
    V-41 N-(2-aminophenyl)-4-[(7-methoxy-6-(3-morpholinylpropoxy)quinazoline-4-amino)methyl]benzamide,
    V-42 N-(2-amino-4-pyridyl)-4-[(7-methoxy-6-(3-morpholinylpropoxy)quinazoline-4-amino)methyl]benzamide,
    V-43 N-(2-aminophenyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide,
    V-44 N-(2-amino-4-pyridyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide,
    V-45 N-(2-amino-5-(2-furyl)phenyl)-4-[(8-fluoroquinazoline-4-amino)methyl)]benzamide,
    V-46 N-(2-aminophenyl)-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide,
    V-47 N-(2-amino-4-pyridyl)-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide, or
    V-48 N-[2-amino-5-(2-furyl)phenyl]-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide.


Their structures are as follows:







TABLE 1







Structures of the prefered compounds








Serial



number
Structure





V-1






 


V-2






 


V-3






 


V-4






 


V-5






 


V-6






 


V-7






 


V-8






 


V-9






 


V-10






 


V-11






 


V-12






 


V-13






 


V-14






 


V-15






 


V-16






 


V-17






 


V-18






 


V-19






 


V-20






 


V-21






 


V-22






 


V-23






 


V-24






 


V-25






 


V-26






 


V-27






 


V-28






 


V-29






 


V-30






 


V-31






 


V-32






 


V-33






 


V-34






 


V-35






 


V-36






 


V-37






 


V-38






 


V-39






 


V-40






 


V-41






 


V-42






 


V-43






 


V-44






 


V-45






 


V-46






 


V-47






 


V-48













The compound of the present invention can be synthesized by the following methods:
General Method I:




Raw material 1 (10 mmol) and raw material IIa (10 mmol) are dissolved in 50 ml water and 4.2 ml concentrated HCl (12 mol/L), and react under reflux for about 0.1-5 h. The reaction is then stopped and subjected to filtration to provide Intermediate IIIa upon drying.
Intermediate IIIa (1 mmol), Compound IV (1 mmol), and O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethylisouronium hexafluorophosphate (HBTU) (0.379 g, 1 mmol) are added sequentially into 10 ml solvent A, and added with triethylamine (2 mmol) dropwise while being kept in an ice bath. The reaction mixture is then stirred at room temperature for 4 h. Subsequently, the reaction mixture is poured into ice water, adjusted with HCl to a pH of about 7-9, and extracted with dichloromethane. The organic phase is dried over anhydrous magnesium sulphate, filtered and concentrated. The residue is purified through column chromatography or recrystallization to provide the target compound V.
General Method II:




Raw material I (10 mmol) and raw material IIb (11 mmol) are dissolved in 30 ml isopropanol and further added with 4 ml triethylamine. The reaction mixture is reacted under reflux for 10 h followed by cooling to room temperature, and then added with a proper amount of water and extracted with ethyl acetate three times. The ethyl acetate layer is collected, dried over anhydrous magnesium sulphate for 3 h and filtered. Intermediate IIIb is obtained after removing the solvent by evaporation.
To Intermediate IIIb (0.01 mol) are added 1.32 g (0.033 mol) sodium hydroxide and then ethanol/water (50 ml/5 ml). The mixture is stirred at 50° C. for 4 h and then concentrated by removing the reaction solvent through evaporation. A proper amount of water is added before filtration. The pH of the filtrate is adjusted with HCl to 4-5. A huge amount of white precipitates are produced, filtered out and dried to provide Intermediate IIIc.
Intermediate IIIc (1 mmol), Compound IV (1 mmol), and O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethylisouronium hexafluorophosphate (HBTU) (0.379 g, 1 mmol) are added sequentially into 10 ml solvent A, and added with triethylamine (2 mmol) dropwise while being kept in an ice bath. The reaction mixture is then stirred at room temperature for 4 h. Subsequently, the reaction mixture is poured into ice water, adjusted with HCl to a pH of about 7-9, and extracted with dichloromethane. The organic phase is dried over anhydrous magnesium sulphate, filtered and concentrated. The residue is purified through column chromatography or recrystallization to provide the target compound V.
General Method III (Synthesis of Compound I):




In the General Method III above, R6 is hydrogen, methyl, ethyl or isopropyl.
Compound VI (0.05 mol) are dissolved in 50 ml glacial acetic acid and added with 13 ml, 65-68% by weight of nitric acid dropwise while being stirred in an ice bath. The reaction mixture is then stirred at room temperature for 24 h before poured into 500 ml ice water and extracted with ethyl acetate. The organic phase is combined and washed three times with saturated NaHCO3 aqueous solution, followed by washing with saturated NaCl solution, drying over anhydrous MgSO4, and filtration. The filtrate is concentrated to provide Compound VII. Compound VII (0.10 mol), ammonium formate (63 g, 1.00 mol), 5% Pd—C (5.00 g) and formamide (75 ml) are reacted at 150° C. for 6.5 h. The reaction mixture is cooled to room temperature and a solid is precipitated. The white solid Compound VIII is obtained after filtration. Thionyl chloride (14.9 g) (oxalyl chloride or phosphorus oxychloride) is added dropwise to a solution of Compound VIII (0.15 mol) in N,N-dimethyl formamide (1 ml) and dichloromethane (150 ml) at room temperature while stirring. Upon the addition, the reaction mixture is heated to reflux for 6 h. Cool the reaction mixture to room temperature. Adjust the pH to 7-8 with NaOH aqueous solution. Leave it to separate and take the organic phase to concentrate under reduced pressure. Compound I is thus obtained.
R1, R2, R3, R4, Y, X1 and m in the above General Methods have the same meanings as described before;
In the previous description, solvent A can be: methanol, ethanol, acetonitrile, dichloromethane, N,N-dimethyl formamide, or the like.
Compounds IIa, IIb, IV, VI and HBTU etc. are commercially available.
It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention has very strong inhibitory effects on HDACs (Example 49), exhibiting comparative inhibitory activities relative to a similar drug currently being investigated in an abroad clinical trial, MS-275, at concentrations of 2 mM, 200 μM, and 40 μM. Among the compounds, Compounds V-4, V-6, V-14, V-17, V-27, V-33 and V-42 etc. have significantly stronger inhibitory activities than MS-275, and according to the in vitro IC50 value against HDACs, Compounds V-4, V-6, V-10, V-11, V-14, V-17. V-27. V-33 and V-42 etc. have better inhibitory activities than MS-275. For example, the IC50 value of V-6 against HDACs is 1.83 μM and the IC50 value of MS-275 against HDACs is 3.52 μM.
It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention shows distinct inhibitory effect on the tumor-associated subtype of HDACs, HDAC1 (Example 50). For example, the inhibitory activities against HDAC1 of Compounds V-7, V-13, V-15, V-16. V-17, V-18. V-19, V-20, V-21, V-24, V-26, and V-27 etc. at both concentrations 10 μM and 1 μM are all superior to that of MS-275, wherein the inhibitory activity against HDAC1 of Compound V-27 shown by its IC50=212 nM is significantly stronger than that of MS-275 (IC50=668 nM), indicating a stronger targeting capacity towards HDAC subtypes.
It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention shows stronger differentiation induction and anti-proliferative effects on multiple strains of tumor cells. Especially, for Hut78 T lymphocytic leukemia cells, Jurkat E6-1 human T-cell lymphoma, PANC-1 human pancreatic cancer cells, A549 human lung cancer cells, K562 human chronic myelogenous leukemia cells, Hep3B2.1-7 human liver cancer cells, MDA-MB-435s human breast cancer cells, Colo320 human colorectal cancer cell lines, and PC-3 human prostate cancer, the anti-proliferative effects are significant (Example 51). Better anti-proliferative effects are observed at both concentrations of 100 μM and 10 μM and the inhibition percentages of Compounds V-9, V-14, V-17, V-19, V-20, V-21. V-24, V-26, and V-27 etc. for multiple strains of tumor cells are superior to that of MS-275. When compared with MS-275, Compound V-27 shows significantly stronger inhibitory effect against tumor cells such as Hut78. K562, and Jurkat E6-1, and stronger inhibitory activity towards Hep3B2.1-7 human liver cancer cells, in which case it has a IC50=1.523 μM, significantly better than MS-275 (IC50=6.816 μM).
It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention is less toxic. The maximum tolerance doses of Compounds V-1, V-4, V-6, V-9, V-13, V-17, V-20, V-25, V-29, V-43, and V-47 when administrated intragastrically are over 5000 mg/kg in mice, and the same of Compounds V-2, V-5, V-1, V-14, V-18, V-22, V-24, V-27 and V-46 are over 2000 mg/kg (Example 52).
It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention has smaller cardiotoxicity than another HDAC inhibitor SAHA. For example, the IC50 values of Compounds V-9 and V-27 for their effects on hERG potassium current are both above 10 μM, indicating a better cardiac safety (Example 53).
It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention provides promising preliminary pharmacokinetic data, showing longer intravenous half-life (1 ̃2 h), higher oral bioavailability (15% ̃45%), and better druggability (Example 54)
It is demonstrated by the pharmacological experiment conducted in vivo in animals that, the compound or a salt thereof according to the present invention has significant antitumor effect on the nude mice xenograft model (Example 55). Among the compounds, Compound V-27 shows significant antitumor effect on the nude mice xenograft model A549. At a dose of 50 mg/kg, Compound V-27 can significantly inhibit the growth of tumor, showing an efficacy equivalent to that of the positive control MS-275 at the same dose, but presenting no mortality and significant weight loss in nude mice and indicating lower adverse side effect. MS-275 is a medicament currently being investigated in an abroad phase II clinical trial.
In conclusion, the compound or a salt thereof according to the present invention not only has distinct inhibitory effect on HDACs and the tumor-associated subtype thereof, HDAC1, but also has stronger differentiation induction and anti-proliferative activities for multiple strains of tumor cells. When compared to a similar drug currently being investigated in an abroad clinical trial, MS-275, the compound of the present invention has apparent advantages in its inhibitory activity or antitumor activity, and more than that, it has the following advantages: smaller toxicity, higher cardiac safety, better preliminary pharmacokinetic data, significant antitumor effect on the nude mice xenograft model, comparable efficacy to that of the positive control MS-275, low adverse side effect, and better druggability. The development of the compound or a salt thereof according to the present invention to a medicament for treating cancers and diseases related to cell differentiation and proliferation is novel, inventive and practical, and worth further investigation.
The present invention further relates to a composition comprising a therapeutically effective amount of the compound or a salt thereof according to the present invention and a pharmaceutically acceptable carrier, wherein the carrier can be any substances commonly used as a carrier such as flavors, sweeteners, liquid or solid fillers, diluents or the like, and the composition of the invention can be formulated with a method well-known in this field into a common pharmaceutical formulation such as in the form of tablet, capsule, powder, syrup, liquid, suspension or injection, typically comprising 1-70% by weight and preferably 5-50% by weight of the active ingredient.
Clinically, the compound according to the present invention can be administrated orally or by injection to a mammal (including human), wherein oral administration is mostly preferred. The administration dose can be 0.0001 ̃200 mg/kg body weight per day. The optimal dose varies depending on the individuals, usually starting with a smaller dose and gradually increasing the amount.
The advantage of the present invention is that said compound and the pharmaceutical formulation thereof have a very good efficacy in treating diseases caused by abnormal gene expression such as tumors, endocrine disorders, immune system diseases, genetic diseases and nervous system diseases.


EMBODIMENTS OF THE INVENTION
The present invention will be further illustrated below by reference to the following Examples. It is to be understood that this invention is not limited to the Examples. All percentages present in the present invention are weight percentages, unless otherwise specified.
EXAMPLE 1
V-1 N-(2-aminophenyl)-4-(quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (intermediate M-1) of the weight 2.47 g was obtained with 4-chloroquinazoline (1.64 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 94%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.231 g was obtained with M-1 (0.265 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 65.1%.
MS (ESI): [M+H]+=356
1H-NMR (400 MHz, DMSO-d6) δppm: 4.86 (s, 2H), 6.62 (t, 1H, J=6.4 Hz), 6.80 (d, 1H, J=8.0 Hz), 6.98 (t, 1H, J=7.6 Hz), 7.20 (d, 1H, J=8.0 Hz), 7.79-8.11 (m, 7H), 8.49 (dd, 1H, J=2.0 Hz, 6.0 Hz), 8.58 (s, 1H), 9.58 (s, 1H), 9.86 (s, 1H).
EXAMPLE 2
V-2 N-(2-amino-4-pyridyl)-4-(quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.227 g was obtained with M-1 (0.265 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 63.9%.
MS (ESI): [M+H]+=357
1H-NMR (400 MHz, DMSO-d6) δppm: 4.76 (s, 2H), 6.59 (t, 1H, J=6.0 Hz), 6.80 (d, 1H, J=7.6 Hz), 6.98 (m, 1H), 7.16 (d, 1H, J=8.0 Hz), 7.74-8.11 (m, 6H), 8.49 (m, 1H), 8.61 (s, 1H), 9.53 (s, 1H), 9.86 (s, 1H).
EXAMPLE 3
V-3 N-(2-amino-5-fluorophenyl)-4-(quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.19 g was obtained with M-1 (0.265 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 50.9%.
MS (ESI): [M+H]+=374
1H-NMR (400 MHz, DMSO-d6) δppm: 4.77 (s, 2H), 6.59 (t, 1H, J=6 Hz), 6.80 (d, 1H, J=8.0 Hz), 6.98 (m, 1H), 7.20 (d, 1H, J=8.0 Hz), 7.78-8.14 (m, 6H), 8.49 (m, 1H), 8.69 (s, 1H), 9.58 (s, 1H), 9.89 (s, 1H)
EXAMPLE 4
V-4 N-(2-amino-4-pyridyl)-4-(6,7-dimethoxyquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-4) of the weight 2.44 g was obtained with 6,7-dimethoxy-4-chloroquinazoline (2.24 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 75%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.282 g was obtained with M-4 (0.325 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 67.9%.
MS (ESI): [M+H]+=417
1H-NMR (400 MHz, DMSO-d6) δppm: 3.90 (s, 6H), 5.13 (s, 2H), 7.11 (s, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.49 (d, 2H, J=8.0 Hz), 7.68 (s, 1H), 7.78 (d, 1H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.65 (s, 1H).
EXAMPLE 5
V-5 N-(2-aminophenyl)-4-(6-methoxyquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-5) of the weight 2.42 g was obtained with 6-methoxy-4-chloroquinazoline (1.94 g, 100 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 82%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.201 g was obtained with M-5 (0.295 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 52.1%.
MS (ESI): [M+H]+=386
1H-NMR (400 MHz, DMSO-d6) δppm: 3.87 (s, 3H), 5.11 (s, 2H), 7.11 (m, 2H), 7.42 (d, 1H, J=5.2 Hz), 7.49 (m, 2H), 7.68 (s, 1H), 7.78 (d, 1H, J=4.8 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.32 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.71 (s, 1H).
EXAMPLE 6
V-6 N-(2-amino-5-fluorophenyl)-4-(6-methoxyquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.276 g was obtained with M-5 (0.295 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 68.3%.
MS (ESI): [M+H]+=404
1H-NMR (400 MHz, DMSO-d6) δppm: 3.83 (s, 3H), 5.11 (s, 2H), 6.79 (m, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.47 (m, 2H), 7.68 (s, 1H), 7.78 (d, 1H, J=4.8 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.32 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.71 (s, 1H).
EXAMPLE 7
V-7 N-(2-aminophenyl)-4-(5-methoxy-quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-7) of the weight 2.69 g was obtained with 5-methoxy-4-chloroquinazoline (1.94 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 91%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.191 g was obtained with M-7 (0.295 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 49.6%.
MS (ESI): [M+H]+=386
1H-NMR (400 MHz, DMSO-d6) δppm: 3.81 (s, 3H), 5.34 (s, 2H), 6.88 (m, 2H), 7.35 (m, 1H), 7.49 (m, 2H), 7.68 (s, 1H), 7.78 (d, 1H, J=4.8 Hz), 7.90 (m, 2H), 8.14 (s, 1H), 8.32 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.80 (s, 1H).
EXAMPLE 8
V-8 N-(2-amino-4-pyridyl)-4-(5-methoxy-quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.224 g was obtained with M-7 (0.295 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol). HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 57.9%.
MS (ESI): [M+H]+=387
1H-NMR (400 MHz, DMSO-d6) δppm: 3.77 (s, 3H), 5.34 (s, 2H), 6.88 (m, 2H), 7.50 (m, 2H), 7.68 (s, 1H), 7.78 (d, 1H, J=4.8 Hz), 7.90 (m, 2H), 8.14 (s, 1H), 8.32 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.80 (s, 1H)
EXAMPLE 9
V-9 N-(2-aminophenyl)-4-(8-methoxy-quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-9) of the weight 2.51 g was obtained with 8-methoxy-4-chloroquinazoline (1.94 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 85%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.181 g was obtained with M-9 (0.295 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol). N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 47.1%.
MS (ESI): [M+H]+=386
1H-NMR (400 MHz, DMSO-d6) δppm: 3.81 (s, 3H), 5.82 (s, 2H), 6.88 (m, 2H), 7.35 (m, 1H), 7.49 (m, 2H), 7.68 (s, 1H), 7.70 (d, 1H, J=4.8 Hz), 7.90 (m, 2H), 8.11 (s, 1H), 8.32 (s, 1H), 8.50 (t, 1H, J=6.0 Hz), 9.77 (s, 1H).
EXAMPLE 10
V-10 N-(2-amino-5-fluorophenyl)-4-(8-methoxy-quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.182 g was obtained with M-9 (0.295 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 45.1%.
MS (ESI): [M+H]+=404
1H-NMR (400 MHz, DMSO-d6) δppm: 3.81 (s, 3H), 5.82 (s, 2H), 6.92 (m, 1H), 7.35 (m, 1H), 7.45 (m, 2H), 7.61 (s, 1H), 7.70 (d, 11, J=4.8 Hz), 7.84 (m, 2H), 8.11 (s, 1H), 8.32 (s, 1H), 8.50 (t, 1H, J=6.0 Hz), 9.88 (s, 1H).
EXAMPLE 11
V-11 N-(2-aminophenyl)-4-(6-nitroquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a pale yellow solid (Intermediate M-11) of the weight 2.79 g was obtained with 6-nitro-4-chloroquinazoline (2.09 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 90%.
Following the General Method I for the preparation of the final product V, a yellow solid of the weight 0.118 g was obtained with M-11 (0.310 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 29.5%.
MS (ESI): [M+H]+=401
1H-NMR (400 MHz. DMSO-d6) δppm: 5.16 (s, 2H), 7.46 (d, 1H, J=5.2 Hz), 7.81 (d, 1H, J=5.2 Hz), 7.94-8.06 (m, 6H), 8.11 (s, 1H), 8.55 (dd, 1H, J=2.0 Hz, 9.2 Hz), 8.77 (s, 1H), 9.65 (s, 1H), 10.58 (s, 1H).
EXAMPLE 12
V-12 N-(2-aminophenyl)-4-(6-fluoroquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-12) of the weight 2.66 g was obtained with 6-fluoro-4-chloroquinazoline (1.82 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 94%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.192 g was obtained with M-12 (0.283 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 51.3%.
MS (ESI): [M+H]+=374
1H-NMR (400 MHz, DMSO-d6) δppm: 4.88 (s, 2H), 6.62 (t, 1H, J=7.2 Hz), 6.80 (d, 1H, J=8.0 Hz), 6.98 (t, 1H, J=7.6 Hz), 7.20 (d, 1H, J=8.0 Hz), 7.81-8.11 (m, 6H), 8.49 (dd, 1H, J=2.4 Hz, 6.4 Hz), 8.69 (s, 1H), 9.58 (s, 1H), 9.89 (s, 1H).
EXAMPLE 13
V-13 N-(2-aminophenyl)-4-(7-fluoroquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-13) of the weight 2.46 g was obtained with 7-fluoro-4-chloroquinazoline (1.82 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 87%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.176 g was obtained with M-13 (0.283 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 47.1%.
MS (ESI): [M+H]+=374
1H-NMR (400 MHz, DMSO-d6) δppm: 4.80 (s, 2H), 6.62 (t, H, J=7.2 Hz), 6.80 (d, 1H, J=8.0 Hz), 6.98 (t, 1H, J=7.6 Hz), 7.20 (d, 1H, J=8.0 Hz), 7.81-8.11 (m, 6H), 8.49 (dd, 1H, J=2.4 Hz, 6.4 Hz), 8.69 (s, 1H), 9.58 (s, 1H), 9.89 (s, 1H).
EXAMPLE 14
V-14 N-(2-amino-5-fluorophenyl)-4-(8-fluoroquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-14) of the weight 2.23 g was obtained with 8-fluoro-4-chloroquinazoline (1.82 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 79%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.211 g was obtained with M-14 (0.283 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 53.8%.
MS (ESI): [M+H]+=392
1H-NMR (400 MHz, DMSO-d6) δppm: 4.80 (s, 2H), 6.62 (t, 1H, J=7.2 Hz), 6.80 (d, 1H, J=8.0 Hz), 6.98 (t, 1H, J=7.6 Hz), 7.20 (d, 1H, J=8.0 Hz), 7.81-8.11 (m, 5H), 8.49 (dd, 1H, J=2.4 Hz, 6.4 Hz), 8.69 (s, 1H), 9.58 (s, 1H), 9.89 (s, 1H).
EXAMPLE 15
V-15 N-(2-aminophenyl)-4-(6,7-dimethoxyethoxyquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-15) of the weight 3.37 g was obtained with 6,7-dimethoxyethoxy-4-chloroquinazoline (3.12 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 82%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.311 g was obtained with M-15 (0.413 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 61.8%.
MS (ESI): [M+H]+=504
1H-NMR (400 MHz. DMSO-d6) δppm: 3.35 (s, 6H), 3.75 (m, 4H), 4.24 (m, 2H), 4.84 (m, 4H), 6.59 (dt, 1H, J=1.2 Hz, 7.6 Hz), 6.77 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.97 (dt, 1H, J=1.2 Hz, 7.6 Hz), 7.17 ((m, 2H), 7.48 (d, 2H, J=8.0 Hz), 7.70 (s, 1H), 7.93 (d, 2H, J=8.4 Hz), 8.31 (s, 1H), 8.47 (t, 1H, J=6.0 Hz), 9.54 (s, 1H).
EXAMPLE 16
V-16 N-(2-amino-4-pyridyl)-4-(6,7-dimethoxyethoxy quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.307 g was obtained with M-15 (0.413 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 60.8%.
MS (ESI): [M+H]+=505
1H-NMR (400 MHz, DMSO-d6) δppm: 3.31 (s, 6H), 3.74 (m, 4H), 4.23 (m, 2H), 4.82 (m, 4H), 6.55 (dt, 1H, J=2 Hz, 7.6 Hz), 6.77 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.94 (dt, 1H, J=1.2 Hz, 7.6 Hz), 7.16 ((m, 2H), 7.48 (m, 1H), 7.66 (s, 1H), 7.93 (d, 2H, J=8.4 Hz), 8.30 (s, 1H), 8.46 (t, 1H, J=6.0 Hz), 9.50 (s, 1H).
EXAMPLE 17
V-17 N-(2-aminophenyl)-4-[7-methoxy-6-(3-morpholinyl propoxy)quinazoline-4-amino]benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (intermediate M-17) of the weight 3.03 g was obtained with 7-methoxy-6-(3-morpholinylpropoxy)-4-chloroquinazoline (3.37 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 69%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.409 g was obtained with M-17 (0.438 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 77.5%.
MS (ESI): [M+H]+=529
1H-NMR (400 MHz, DMSO-d6) δppm: 1.82 (m, 2H), 2.31-2.47 (m, 6H), 3.65 (m, 4H), 3.90 (s, 3H), 4.06 (m, 2H), 5.13 (s, 2H), 7.11 (s, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.49 (d, 2H, J=8.0 Hz), 7.68 (s, 1H), 7.78 (d, 1H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.54 (1, 1H, J=6.0 Hz), 9.65 (s, 1H).
EXAMPLE 18
V-18 N-(2-amino-5-fluorophenyl)-4-[7-methoxy-6-(3-morpholinylpropoxy)quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.334 g was obtained with M-17 (0.438 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 61.2%.
MS (ESI): [M+H]+=547
1H-NMR (400 MHz, DMSO-d6) δppm: 1.80 (m, 2H), 2.35-2.51 (m, 6H), 3.69 (m, 4H), 3.90 (s, 3H), 4.05 (m, 2H), 5.10 (s, 2H), 7.41 (d, 1H, J=5.6 Hz), 7.49 (d, 2H, J=8.0 Hz), 7.68 (s, 1H), 7.78 (d, 1H, J=5.6 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.06 (s, 1H), 8.41 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.77 (s, 1H).
EXAMPLE 19
V-19 N-(2-aminophenyl)-4-[6-(5-((2-(methylsulfonyl)ethylamino)methyl)furyl)quinazoline-4-amino]benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-19) of the weight 3.75 g was obtained with 6-(5-((2-(methylsulfonyl)ethylamino)methyl)furyl)-4-chloroquinazoline (3.65 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 80%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.319 g was obtained with M-19 (0.466 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 57.4%.
MS (ESI): [M+H]+=557
1H-NMR (400 MHz, DMSO-d6) δppm: 2.83 (s, 3H), 3.11 (m, 2H), 3.53 (m, 2H), 3.66 (d, 1H, J=5.6 Hz), 5.19 (s, 2H), 6.26 (m, 1H), 6.79 (m, 1H), 6.99-7.01 (m, 2H), 7.41 (d, 1H, J=5.6 Hz), 7.49 (d, 2H, J=8.0 Hz), 7.70 (m, 2H), 7.92-8.06 (m, 3H), 8.22 (m, 1H), 8.49 (s, 1H), 9.21 (s, 1H), 9.67 (s, 1H).
EXAMPLE 20
V-20 N-(2-amino-5-fluorophenyl)-4-[6-(5-((2-(methyl sulfonyl)ethylamino)methyl)furyl)quinazoline-4-amino)]benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.298 g was obtained with M-19 (0.466 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 51.8%.
MS (ESI): [M+H]+=575
1H-NMR (400 MHz, DMSO-d6) δppm: 2.85 (s, 3H), 3.11 (m, 2H), 3.53 (m, 2H), 3.67 (d., H, J=5.6 Hz), 5.19 (s, 2H), 6.26 (m, 1H), 6.59 (m, 1H), 6.73 (m, 1H), 7.01 (m, 1H), 7.45-7.53 (m, 3H), 7.70 (m, 2H), 8.06 (m, 2H), 8.22 (m, 1H), 8.49 (s, 1H), 9.21 (s, 1H), 9.60 (s, 1H).
EXAMPLE 21
V-21 N-(2-aminophenyl)-4-(6-acetamidoquinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-21) of the weight 2.71 g was obtained with 6-acetamido-4-chloroquinazoline (2.21 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 84%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.248 g was obtained with M-21 (0.322 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 60.2%.
MS (ESI): [M+H]+=413
1H-NMR (400 MHz, DMSO-d6) δppm: 2.04 (s, 3H), 4.84 (m, 2H), 6.59 (dt, 1H, J=1.2 Hz, 7.2 Hz), 6.77 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.96 (dt, 1H, J=1.2 Hz, 8.0 Hz), 7.17 (dd, 1H, J=1.2 Hz, 8.0 Hz), 7.49 (d, 2H, J=8.4 Hz), 7.72 (d, 1H, J=8.8 Hz), 7.79 (dd, 1H, J=1.2 Hz, 8.8 Hz), 7.93 (d, 2H, J=8.0 Hz), 8.48 (m, 2H), 8.94 (t, 1H, J=5.6 Hz), 9.55 (s, 1H), 10.71 (s, 1H).
EXAMPLE 22
V-22 N-(2-aminophenyl)-4-(6-methoxycarbonylmethyl quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the intermediate IIIa, a white solid (Intermediate M-22) of the weight 2.11 g was obtained with 6-methoxycarbonylmethyl-4-chloroquinazoline (2.36 g, 10 mmol) (prepared according to General Method III) and p-aminobenzoic acid (1.37 g, 10 mmol). The yield was 63%.
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.201 g was obtained with M-22 (0.337 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 47.1%.
MS (ESI): [M+H]+=428
1H-NMR (400 MHz, DMSO-d6) δppm: 3.63-3.75 (m, 6H), 5.19 (s, 2H), 6.79 (m, 1H), 6.98 (m, 1H), 7.40 (d, 1H, J=5.6 Hz), 7.53 (m, 2H), 7.68-7.81 (m, 4H), 8.00 (m, 1H), 8.49 (s, 1H), 9.21 (s, 1H), 9.51 (s, 1H).
EXAMPLE 23
V-23 N-[2-amino-5-(2-thienyl)phenyl]-4-(6,7-dimethoxy quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.243 g was obtained with M-4 (0.325 g, 1 mmol), 4-(2-thienyl)-1,2-phenylenediamine (0.190 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 49.9%.
MS (ESI): [M+H]+=498
1H-NMR (400 MHz, DMSO-d6) δppm: 3.90 (s, 6H) 5.13 (s, 2H), 7.11 (s, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.49-7.68 (m, 3H), 7.78 (d, 1H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.44 (t, 1H, J=6.0 Hz), 9.67 (s, 1H).
EXAMPLE 24
V-24 N-[2-amino-5-(phenyl)phenyl]-4-(6,7-dimethoxy quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.198 g was obtained with M-4 (0.325 g, 1 mmol), 4-phenyl-1,2-phenylenediamine (0.184 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 40.3%.
MS (ESI): [M+H]+=492
1H-NMR (400 MHz, DMSO-d6) δppm: 3.83 (s, 6H), 5.19 (s, 2H), 6.60 (m, 1H), 7.22-7.29 (m, 2H), 7.40-7.61 (m, 8H), 7.71 (m, 2H), 7.84 (s, 1H), 8.49 (s, 1H), 9.21 (s, 1H), 9.51 (s, 1H).
EXAMPLE 25
V-25 N-[2-amino-5-(2-furyl)phenyl]-4-(6,7-dimethoxy quinazoline-4-amino)benzamide
Following the General Method I for the preparation of the final product V, a white solid of the weight 0.104 g was obtained with M-4 (0.325 g, 1 mmol), 4-(2-furyl)-1,2-phenylenediamine (0.174 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 21.6%.
MS (ESI): [M+H]+=482
1H-NMR (400 MHz, DMSO-d6) δppm: 3.92 (s, 6H) 5.11 (s, 2H), 7.13 (s, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.49-7.68 (m, 3H), 7.78 (d, 1H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.30 (s, 1H), 8.41 (t, 1H, J=6.0 Hz), 9.65 (s, 1H).
EXAMPLE 26
V-26 N-(2-amino-4-pyridyl)-4-((quinazoline-4-amino)methyl benzamide
Following the General
Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-26) of the weight 2.01 g was obtained with 4-chloroquinazoline (1.64 g, 10 mmol) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 72%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.234 g was obtained with M-26 (0.279 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 63.3%.
MS (ESI): [M+H]+=371
1H-NMR (400 MHz, DMSO-d6) δppm: 3.90 (s, 6H), 4.85 (d, 2H, J=5.6 Hz), 5.13 (s, 2H), 7.11 (s, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.49 (d, 2H, J=8.0 Hz), 7.68 (s, 1H), 7.78 (d, 1H, J=5.2 Hz), 7.90) (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.65 (s, 1H)
EXAMPLE 27
V-27 N-(2-aminophenyl)-4-[(quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.177 g was obtained with M-26 (0.279 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 47.8%.
MS (ESI): [M+H]+=370
1H-NMR (400 MHz, DMSO-d6) δppm: 4.82 (s, 2H), 4.86 (d, 2H, J=6.0 Hz), 6.59 (t, 1H, J=7.4 Hz), 6.77 (d, 2H, J=6.8 Hz), 6.55 (dt, 1H, J=1.2 Hz, 7.6 Hz), 7.17 (d, 1H, J=7.6 Hz), 7.48 (d, 2H, J=8.0 Hz), 7.55 (t, 1H, J=8.0 Hz), 7.71 (d, 1H, J=8.4 Hz), 7.79 (t, 1H, J=8.0 Hz), 7.92 (d, 2H, J=8.0 Hz), 8.31 (d, 1H, J=8.0 Hz), 8.45 (s, 1H), 8.86 (t, 1H, J=6.0 Hz), 9.53 (s, 1H)
EXAMPLE 28
V-28 N-[2-amino-5-(2-thienyl)phenyl]-4-[(quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.219 g was obtained with M-26 (0.279 g, 1 mol), 4-(2-thienyl)-1,2-phenylenediamine (0.190 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 48.5%.
MS (ESI): [M+H]+=452
1H-NMR (400 MHz, DMSO-d6) δppm: 4.81 (s, 2H), 4.86 (d, 2H, J=5.6 Hz), 6.57 (t, 1H, J=7.4 Hz), 6.77 (d, 2H, J=6.4 Hz), 6.55 (dt, 1H, J=1.2 Hz, 7.6 Hz), 7.17 (d, 1H, J=7.6 Hz), 7.48-7.69 (m, 3H), 7.71 (d, 1H, J=8.4 Hz), 7.79 (t, 1H, J=8.0 Hz), 7.92 (d, 2H, J=8.0 Hz), 8.31 (d, 1H, J=8.0 Hz), 8.45 (s, 1H), 8.86 (t, 1H, J=6.0 Hz), 9.53 (s, 1H)
EXAMPLE 29
V-29 N-(2-amino-5-fluorophenyl)-4-[(quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.208 g was obtained with M-26 (0.279 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 53.6%.
MS (ESI): [M+H]+=388
1H-NMR (400 MHz, DMSO-d6) δppm: 4.85 (d, 2H, J=6.4 Hz), 5.17 (s, 2H), 6.35 (dt, 1H, J=2.8 Hz, 8.4 Hz), 6.52 (dd, 1H, J=2.8 Hz, 11.2 Hz), 7.10 (dt, 1H. J=2.0 Hz, 8.4 Hz), 7.46 (d, 2H, J=7.6 Hz), 7.55 (t, 11, J=7.4 Hz), 7.70 (d, 1H, J=7.6 Hz), 7.79 (t, 1H, J=7.6 Hz), 7.91 (d, 2H, J=8.0 Hz), 8.31 (d, 11, J=7.6 Hz), 8.44 (s, 1H), 8.90 (t, 1H, J=6.0 Hz), 9.50 (s, 1H)
EXAMPLE 30
V-30 N-(2-amino-4-pyridyl)-4-[(6,7-dimethoxyquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-30) of the weight 2.01 g was obtained with 6,7-dimethoxy-4-chloroquinazoline (2.24 g, 1 (10 mol) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 59%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.275 g was obtained with M-30 (0.339 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 63.9%.
MS (ESI): [M+H]+=431
1H-NMR (400 MHz, DMSO-d6) δppm: 3.90 (s, 6H), 4.85 (d, 2H, J=5.6 Hz), 5.13 (s, 2H), 7.11 (s, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.49 (d, 211, J=8.0 Hz), 7.68 (s, 1H), 7.78 (d, 1H, J=5.2 Hz), 7.92 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.54 (t, 1H, J=6.0 Hz), 9.65 (s, 1H)
EXAMPLE 31
V-31 N-[2-amino-5-(2-thienyl)phenyl]-4-[(6,7-dimethoxyquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.231 g was obtained with M-30 (0.339 g, 1 mmol), 4-(2-thienyl)-1,2-phenylenediamine (0.190 g, 1 mmol). HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 45.1%.
MS (ESI): [M+H]+=512
1H-NMR (400 MHz, DMSO-d6) δppm: 3.90 (s, 6H), 4.85 (d, 2H, J=5.6 Hz), 5.13 (s, 2H), 7.11 (s, 1H), 7.42 (d, 1H, J=5.2 Hz), 7.49-7.68 (m, 3H), 7.78 (d, H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.44 (t, 1H, J=6.0 Hz), 9.67 (s, 1H)
EXAMPLE 32
V-32 N-(2-aminophenyl)-4-[(7-methoxyquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-32) of the weight 2.11 g was obtained with 7-methoxy-4-chloroquinazoline (1.94 g, 10 mmol) (prepared according to General Method III) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 68.3%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.198 g was obtained with M-32 (0.309 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 49.6%.
MS (ESI): [M+H]+=400
1H-NMR (400 MHz, DMSO-d6) δppm: 3.86 (s, 3H), 4.84 (d, 2H, J=5.6 Hz), 5.13 (s, 2H), 7.11 (m, 2H), 7.43 (d, 1H, J=6.0 Hz), 7.47 (d, 2H, J=8.0 Hz), 7.68 (s, 1H), 7.76 (d, 1H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.07 (s, 1H), 8.33 (s, 1H), 8.51 (t, 1H, J=6.0 Hz), 9.69 (s, 1H)
EXAMPLE 33
V-33 N-(2-aminophenyl)-4-[(6-methoxyquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-33) of the weight 2.01 g was obtained with 6-methoxy-4-chloroquinazoline (1.94 g, 10 mmol) (prepared according to General Method III) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 65%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.177 g was obtained with M-33 (0.309 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol). HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 44.4%.
MS (ESI): [M+H]+=400
1H-NMR (400 MHz, DMSO-d6) δppm: 3.92 (s, 3H), 4.81 (d, 2H, J=5.6 Hz), 5.13 (s, 2H), 7.11 (s, 1H), 7.35-7.43 (m, 2H), 7.47 (d, 2H, J=8.0 Hz), 7.68 (s, 1H), 7.76 (d, 1H, J=5.2 Hz), 7.92 (d, 2H, J=8.0 Hz), 8.11 (s, 1H), 8.39 (s, 1H), 8.51 (t, 1H, J=6.0 Hz), 9.70 (s, 1H)
EXAMPLE 34
V-34 N-(2-aminophenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-34) of the weight 1.98 g was obtained with 8-methoxy-4-chloroquinazoline (1.94 g, 10 mmol) (prepared according to General Method III) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 64%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.154 g was obtained with M-34 (0.309 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 38.6%.
MS (ESI): [M+H]+=400
1H-NMR (400 MHz, DMSO-d6) δppm: 3.90 (s, 3H), 4.85 (d, 2H, J=6.0 Hz), 5.13 (s, 2H), 7.11 (s, 1H), 7.32-7.42 (m, 2H), 7.47 (d, 2H, J=7.6 Hz), 7.67 (s, 1H), 7.78 (d, 1H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.44 (t, 1H, J=6.0 Hz), 9.67 (s, 1H)
EXAMPLE 35
V-35 N-(2-amino-5-fluorophenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.204 g was obtained with M-34 (0.309 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 48.9%.
MS (ESI): [M+H]+=418
1H-NMR (400 MHz, DMSO-d6) δppm: 3.84 (s, 3H), 4.85 (d, 2H, J=5.6 Hz), 5.13 (s, 2H), 7.06 (s, 1H), 7.38-7.42 (m, 1H), 7.47 (d, 211, J=7.6 Hz), 7.67 (s, 1H), 7.78 (d, 1H, J=4.8 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.36 (t, 1H, J=5.6 Hz), 9.61 (s, 1H)
EXAMPLE 36
V-36 N-(2-amino-5-(phenyl)phenyl)-4-[(8-methoxy quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.287 g was obtained with M-34 (0.309 g, 1 mmol), 4-phenyl-1,2-phenylenediamine (0.184 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 60.3%.
MS (ESI): [M+H]+=476
1H-NMR (400 MHz, DMSO-d6) δppm: 3.91 (s, 3H), 4.82 (d, 2H, J=6.0 Hz), 5.13 (s, 2H), 7.17 (s, 1H), 7.32-7.42 (m, 7H), 7.47 (d, 2H, J=7.6 Hz), 7.65 (s, 1H), 7.78 (d, 1H, J=5.2 Hz), 7.90 (d, 2H, J=8.0 Hz), 8.08 (s, 1H), 8.31 (s, 1H), 8.44 (t, 1H, J=6.0 Hz), 9.67 (s, 1H)
EXAMPLE 37
V-37 N-(2-aminophenyl)-4-[(6-nitroquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a yellow solid (Intermediate M-37) of the weight 1.11 g was obtained with 6-nitro-4-chloroquinazoline (2.09 g, 10 mmol) (prepared according to General Method III) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 34.3%.
Following the General Method II for the preparation of the final product V, a yellow solid of the weight 0.210 g was obtained with M-37 (0.324 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 50.7%.
MS (ESI): [M+H]+=415
1H-NMR (400 MHz, DMSO-d6) δppm: 4.87 (s, 2H), 5.17 (m, 2H) 6.62 (dt, 1H, J=1.2 Hz, 8.0 Hz), 6.79 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.98 (dt, 1H, J=1.2 Hz, 8.0 Hz), 7.21 (d, 1H, J=8.0 Hz), 7.97-8.08 (m, 5H), 8.58 (dd, 1H, J=2.4 Hz, 9.2 Hz), 8.80 (s, 1H), 9.59 (s, 1H), 9.70 (d, 1H, J=1.6 Hz), 10.57 (s, 1H)
EXAMPLE 38
V-38 N-(2-aminophenyl)-4-[(6,7-dimethoxyethoxy quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-38) of the weight 1.11 g was obtained with 6,7-dimethoxyethoxy-4-chloroquinazoline (3.12 g, 10 mmol) (prepared according to General Method III) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 34.3%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.267 g was obtained with M-38 (0.427 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 51.7%.
MS (ESI): [M+H]+=518
1H-NMR (400 MHz, DMSO-d6) δppm: 3.35 (s, 6H), 3.75 (m, 4H), 4.24 (m, 4H), 4.84 (m, 4H), 6.59 (dt, 1H, J=1.2 Hz, 7.6 Hz), 6.77 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.97 (dt, 1H, J=1.2 Hz, 7.6 Hz), 7.17 ((m, 2H), 7.48 (d, 2H, J=8.0 Hz), 7.70 (s, 1H), 7.93 (d, 2H, J=8.4 Hz), 8.31 (s, 1H), 8.47 (t, 1H, J=6.0 Hz), 9.54 (s, 1H)
EXAMPLE 39
V-39 N-(2-amino-4-pyridyl)-4-[(6,7-dimethoxyethoxy quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.207 g was obtained with M-38 (0.427 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 40.0%.
MS (ESI): [M+H]+=519
1H-NMR (400 MHz, DMSO-d6) δppm: 3.32 (s, 6H), 3.72 (m, 4H), 4.14 (m, 4H), 4.83 (m, 4H), 6.52 (dt, 1H, J=1.2 Hz, 7.2 Hz), 6.97 (dt, 1H, J=1.2 Hz, 7.2 Hz), 7.13 ((m, 2H), 7.48 (d, 2H, J=8.0 Hz), 7.72 (s, 1H), 7.91 (d, 2H, J=8.4 Hz), 8.30 (s, 1H), 8.45 (t, 1H, J=6.0 Hz), 9.56 (s, 1H)
EXAMPLE 40
V-40 N-(2-amino-5-fluorophenyl)-4-[(6,7-dimethoxyethoxy quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.246 g was obtained with M-38 (0.427 g, 1 mmol), 4-fluoro-1,2-phenylenediamine (0.126 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 45.9%.
MS (ESI): [M+H]+=536
1H-NMR (400 MHz, DMSO-d6) δppm: 3.34 (s, 6H), 3.75 (m, 4H), 4.14 (m, 4H), 4.82 (m, 4H), 6.52 (dt, 1H, J=1.2 Hz, 7.2 Hz), 6.99 (dt, 1H, J=1.2 Hz, 7.2 Hz), 7.13 ((m, 2H), 7.49 (d, 2H, J=8.0H-z), 7.73 (s, 1H), 7.93 (d, 2H, J=8.4 Hz), 8.37 (s, 1H), 8.46 (t, 1H, J=6.0 Hz), 9.55 (s, 1H)
EXAMPLE 41
V-41 N-(2-aminophenyl)-4-[(7-methoxy-6-(3-morpholinyl propoxy)quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-41) of the weight 2.98 g was obtained with 7-methoxy-6-(3-morpholinylpropoxy)-4-chloroquinazoline (3.37 g, 10 mmol) (prepared according to General Method III) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 65.9%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.222 g was obtained with M-41 (0.452 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 41.0%.
MS (ESI): [M+H]+=543
1H-NMR (400 MHz, DMSO-d6) δppm: 1.82 (m, 2H), 2.31-2.47 (m, 6H), 3.65 (m, 4H), 3.90 (s, 3H), 4.84 (m, 4H), 6.59 (dt, 1H, J=1.2 Hz, 7.6 Hz), 6.77 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.97 (dt, 1H, J=1.2 Hz, 8.0 Hz), 7.09 (s, 1H), 7.13 (d, 1H, J=8.0 Hz), 7.46 (d, 2H, J=8.4 Hz), 7.62 (s, 1H), 7.88 (d, 2H, J=8.0 Hz), 8.28 (s, 1H), 8.48 (t, 1H, J=5.6 Hz), 9.53 (s, 1H)
EXAMPLE 42
V-42 N-(2-amino-4-pyridyl)-4-[(7-methoxy-6-(3-morpholinyl propoxy)quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.211 g was obtained with M-41 (0.452 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 38.9%.
MS (ESI): [M+H]+=544
1H-NMR (400 MHz, DMSO-d6) δppm: 1.84 (m, 2H), 2.31-2.47 (m, 6H), 3.67 (m, 4H), 3.90 (s, 3H), 4.84 (m, 4H), 6.59 (dt, 1H, J=1.2 Hz, 7.6 Hz) 6.99 (dt, 1H, J=1.2 Hz, 8.0 Hz), 7.09 (s, 1H), 7.13 (d, 1H, J=8.0 Hz), 7.46 (d, 2H, J=8.4 Hz), 7.61 (s, 1H), 7.82 (d, 2H, J=8.0 Hz), 8.27 (s, 1H), 8.49 (t, 1H, J=5.6 Hz), 9.55 (s, 1H)
EXAMPLE 43
V-43 N-(2-aminophenyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-43) of the weight 1.91 g was obtained with 8-fluoro-4-chloroquinazoline (1.82 g, 10 mmol) (prepared according to General Method III) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 64.3%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.119 g was obtained with M-43 (0.297 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 30.7%.
MS (ESI): [M+H]+=388
1H-NMR (400 MHz, DMSO-d6) δppm: 4.85 (m, 4H), 6.59 (dt, 1H, J=1.2 Hz, 7.6 Hz), 6.77 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.96 (dt, 1, J=1.2 Hz, 8.0 Hz), 7.17 (dd, 1H, J=1.2 Hz, 7.6 Hz), 7.48 (d, 2H, J=8.4 Hz), 7.59 (dd, 1H, J=2.0 Hz, 8.8 Hz), 7.75 (d, 1H, J=2.4 Hz), 7.93 (d, 1, J=8.0 Hz), 8.35 (d, 1H, J=8.8 Hz), 8.47 (s, 1H), 9.00 (t, 1H, J=5.6 Hz), 9.54 (s, 1H)
EXAMPLE 44
V-44 N-(2-amino-4-pyridyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.153 g was obtained with M-43 (0.297 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 39.3%.
MS (ESI): [M+H]+=389
1H-NMR (400 MHz, DMSO-d6) δppm: 4.85 (d, 2H, J=6.0 Hz), 5.17 (s, 2H), 6.35 (dt, 1H, J=2.8 Hz, 8.4 Hz), 6.53 (dd, 1H, J=2.8 Hz, 7.2 Hz), 7.10 (dt, 1H, J=1.6 Hz, 6.8 Hz), 7.46 (d, 2H, J=8.0 Hz), 7.60 (dd, 1H, J=2.4 Hz, 4.8 Hz), 7.74 (d, 1H, J=2.0 Hz), 7.91 (d, 2H, J=8.0 Hz), 8.35 (d, 1H, J=8.8 Hz), 8.46 (s, 1H), 9.04 (t, 1H, J=6.0 Hz), 9.51 (s, 1H)
EXAMPLE 45
V-45 N-(2-amino-5-(2-furyl)phenyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.257 g was obtained with M-43 (0.297 g, 1 mmol), 4-(2-furyl)-1,2-phenylenediamine (0.174 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 56.6%.
MS (ESI): [M+H]+=454
1H-NMR (400 MHz, DMSO-d6) δppm: 4.86 (d, 2H, J=5.6 Hz), 5.13 (s, 2H), 7.42 (d, 2H, J=5.2 Hz), 7.50 (m, 5H,), 7.60 (dd, 1H, J=2.0 Hz, 8.8 Hz), 7.50-7.80 (m, 2H), 7.90 (d, 2H, J=8.0 Hz), 8.09 (s, 1H), 8.35 (d, 1H, J=8.0 Hz), 8.46 (s, 1H), 9.06 (t, 1H, J=5.6 Hz), 9.67 (s, 1H)
EXAMPLE 46
V-46 N-(2-aminophenyl)-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the intermediate IIIc, a white solid (Intermediate M-46) of the weight 2.09 g was obtained with 6-acetamido-4-chloroquinazoline (2.21 g, 10 mmol) (prepared according to General Method II) and methyl 4-(aminomethyl)benzoate hydrochloride (2.22 g, 11 mmol). The yield was 62.2%.
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.119 g was obtained with M-46 (0.336 g, 1 mmol), o-phenylenediamine (0.108 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 30.7%.
MS (ESI): [M+H]+=427
1H-NMR (400 MHz, DMSO-d6) δppm: 2.04 (s, 3H), 4.84 (m, 4H), 6.59 (dt, 1H, J=1.2 Hz, 7.2 Hz), 6.77 (dd, 1H, J=1.2 Hz, 8.0 Hz), 6.96 (dt, 1H, J=1.2 Hz, 8.0 Hz), 7.17 (dd, 1H, J=1.2 Hz, 8.0 Hz), 7.49 (d, 2H, J=8.4 Hz), 7.72 (d, 1H, J=8.8 Hz), 7.79 (dd, 1H, J=1.2 Hz, 8.8 Hz), 7.93 (d, 2H, J=8.0 Hz), 8.48 (m, 2H), 8.94 (t, 1H, J=5.6 Hz), 9.55 (s, 1H), 10.71 (s, 1H)
EXAMPLE 47
V-47 N-(2-amino-4-pyridyl)-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.107 g was obtained with M-46 (0.336 g, 1 mmol), 3,4-diaminopyridine (0.109 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 25%.
MS (ESI): [M+H]+=428
1H-NMR (400 MHz, DMSO-d6) δppm: 2.11 (s, 3H), 4.82 (m, 4H), 6.57 (dt, 1H, J=1.2 Hz, 7.2 Hz), 6.96 (dt, 1H, J=1.2 Hz, 8.0 Hz), 7.19 (dd, 1H, J=1.2 Hz, 8.0 Hz), 7.49 (d, 2H, J=8.4 Hz), 7.71 (d, 1H, J=8.8 Hz), 7.79 (dd, 1H, J=1.2 Hz, 8.8 Hz), 7.93 (d, 2H, J=8.0 Hz), 8.48 (m, 2H), 8.94 (t, 1H, J=5.6 Hz), 9.54 (s, 1H), 1055 (s, 1H)
EXAMPLE 48
V-48 N-[2-amino-5-(2-furyl)phenyl]-4-[(6-acetamido quinazoline-4-amino)methyl]benzamide
Following the General Method II for the preparation of the final product V, a white solid of the weight 0.247 g was obtained with M-46 (0.336 g, 1 mmol), 4-(2-furyl)-1,2-phenylenediamine (0.174 g, 1 mmol), HBTU (0.379 g, 1 mmol), N,N-dimethylformamide (10 ml), and triethylamine (0.202 g, 2 mmol). The yield was 50.1%.
MS (ESI): [M+H]+=493
1H-NMR (400 MHz. DMSO-d6) δppm: 2.04 (s, 3H), 4.84 (m, 4H), 6.59 (dt, 1H, J=1.2 Hz, 7.2 Hz), 6.78-6.96 (m, 3H), 7.17 (dd, 1H, J=1.2 Hz, 8.0 Hz), 7.45 (d, 2H, J=8.4 Hz), 7.72 (d, 1H, J=8.8 Hz), 7.81 (dd, 1H, J=1.2 Hz, 8.8 Hz), 7.93 (d, 2H, J=8.0 Hz), 8.48 (m, 2H), 8.94 (t, 1H, J=5.6 Hz), 9.55 (s, 1H), 10.71 (s, 1H)
EXAMPLE 49
The in vitro inhibitory activities of the compounds towards HDACs were tested according to the instructions in the HDAC Inhibitor Drug Screening Kit (Biovision/Catalog #K340-100).
(1) The compounds to be tested were each individually prepared as 2 mM, 200 μM and 40 μM solutions and their inhibitory activities at these concentrations were tested. Results are as follows:







TABLE 2







In vitro inhibitory effects of the compounds towards HDACs











2 mM
200 μM
40 μM














Inhibition

Inhibition

Inhibition




percentage

percentage

percentage













Compound
(%)
SD
(%)
SD
(%)
SD


















MS-275
82.2
0.2
60.5
0.3
32.5
0.7


1
V-1
65.2
1.1
19.8
2.4
9.4
4.5


2
V-2
77.1
0.5
28.0
2.3
17.6
1.6


3
V-3
78.2
0.4
36.0
1.2
9.5
2.9


4
V-4
85.3
4.3
70.3
1.5
36.3
4.9


5
V-5
36.7
2.1
16.8
2.2
2.8
0.2


6
V-6
87.1
0.2
58.0
0.9
34.5
0.8


7
V-7
39.2
1.0
22.1
1.8
6.5
0.6


8
V-8
46.2
0.2
41.1
0.2
8.9
5.4


9
V-9
50.0
2.2
7.8
2.8
1.9
2.5


10
V-10
77.2
0.1
32.9
0.7
12.0
1.7


11
V-11
49.0
0.9
11.1
1.1
4.1
0.2


12
V-12
85.2
1.7
43.0
3.8
16.8
0.4


13
V-13
50.0
4.0
20.1
0.2
1.0
1.9


14
V-14
94.8
4.4
67.1
0.3
46.8
0.6


15
V-15
61.4
1.7
51.5
0.4
13.7
2.1


16
V-16
58.6
1.6
56.8
0.6
24.8
0.1


17
V-17
86.7
0.3
60.7
0.6
39.7
1.4


18
V-18
66.0
1.9
56.8
1.1
30.4
0.3


19
V-19
72.3
0.7
57.8
0.3
22.7
3.8


20
V-20
67.5
1.5
56.9
1.4
28.2
0.8


21
V-21
79.2
1.3
39.1
1.6
10.1
0.3


22
V-22
84.2
1.3
47.5
0.3
19.9
0.8


23
V-23
40.7
1.3
37.3
3.1
17.5
0.2


24
V-24
76.1
0.4
55.2
0.7
24.2
0.6


25
V-25
72.8
1.1
55.2
0.4
20.5
0.8


26
V-26
82.4
2.0
40.2
2.6
11.4
1.1


27
V-27
91.9
1.0
82.6
1.1
73.2
0.2


28
V-29
37.8
1.4
31.0
1.3
8.6
1.3


29
V-31
69.8
3.4
17.3
2.9
3.5
0.8


30
V-32
42.5
0.4
3.1
2.4
2.2
0.5


31
V-33
88.8
7.1
66.8
1.7
53.2
1.3


32
V-35
81.8
0.1
47.8
0.7
10.1
1.2


33
V-37
65.7
2.2
56.1
0.1
24.0
2.5


34
V-39
85.3
5.7
58.0
0.1
34.3
1.1


35
V-42
90.6
0.9
46.7
0.6
17.2
0.0


36
V-48
85.0
1.2
42.2
2.8
14.0
2.2









(2) The IC50 value of the compound was determined using a concentration gradient from 2000 μM to 7.6E-03 μM containing 10 concentrations obtained by a four times dilution method. The screening concentration range for the reference compound MS-275 was a gradient from 2000 μM to 7.6E-03 μM containing 10 concentrations. Results are as follows:







TABLE 3







IC50 of the compounds for the in vitro inhibition of HDACs










Compound I.D.
IC50 value (μM)







MS-275
3.52



V-4
3.29



V-5
7.79



V-6
1.83



V-7
3.99



V-8
7.76



V-9
4.91



V-10
1.04



V-11
3.11



V-12
0.92



V-13
1.14



V-14
3.77



V-15
9.40



V-16
6.89



V-17
1.72



V-18
1.02



V-19
1.37



V-20
1.22



V-27
1.31



V-33
1.01



V-42
1.67










EXAMPLE 50
The in vitro inhibitory activities of the compounds towards the subtype HDAC1 were tested according to the instructions in the HDAC1 Inhibitor Drug Screening Kit (Biovision).
(1) The compounds to be tested were each individually prepared as 10 μM and 1 μM solutions and their inhibitory activities at these concentrations were tested.
Results are as follows:







TABLE 4







In vitro inhibitory effects of the compounds towards HDAC1










10 μM
1 μM











Compound I.D.
% Inhibition
SD
% Inhibition
SD














MS-275
76.20
0.25
46.58
3.86


V-6
50.09
3.49
6.47
1.98


V-7
78.37
1.87
50.13
5.22


V-8
62.68
1.96
21.38
1.93


V-9
58.26
0.12.
33.76
2.14


V-10
62.62
7.76
45.19
2.75


V-11
33.38
0.27
26.18
7.12


V-12
49.15
3.28
14.98
3.80


V-13.
83.04
11.24
53.13
4.44


V-14
28.86
7.96
1.48
7.44


V-15
78.84
0.88
67.08
9.07


V-16
87.38
0.12
59.13
1.37


V-17
76.18
1.90
53.88
2.83


V-18
80.77
2.60
59.78
0.90


V-19
80.25
2.30
47.64
4.06


V-20
77.38
3.84
53.53
4.28


V-21
86.86
1.21
55.04
0.61


V-22
63.01
0.16
23.08
1.69


V-23
55.78
1.09
19.21
1.55


V-24
73.30
4.28
51.02
3.52


V-25
53.76
1.24
24.22
0.50


V-26
88.37
3.61
46.41
5.32


V-27
83.03
1.35
58.31
1.91


V-29
63.20
0.66
41.39
1.73









(2) The compound to be tested was diluted using DMSO with a four times dilution method to give 10 diluted concentrations, i.e. 500 μM, 125 μM, 31.25 μM, 7.81 μM, 1.95 μM, 0.49 μM, 0.12 μM, 0.03 μM, 7.6 E-03 μM and 1.9 E-03 μM in sequence. Each dilution sample was placed in two wells and the enzyme inhibition IC50 of the compound was tested.







TABLE 5







IC50 of the compounds for the in vitro inhbition of HDAC1










Compound
HDAC1 IC50







MS-275
668 nM



V-17
735 nM



V-18
330 nM



V-23
178 nM



V-27
212 nM



V-29
517 nM










EXAMPLE 51
Determination of the In Vitro Inhibitory Activities of the Compounds Towards Tumor Cells
The inhibitory activities of the compounds towards Hut78 T lymphocytic leukemia cells, Jurkat E6-1 human T-cell lymphoma, PANC-1 human pancreatic cancer cells, A549 human lung cancer cells, K562 human chronic myelogenous leukemia cells, Hep3B2.1-7 human liver cancer cells, MDA-MB-435s human breast cancer cells. Colo320 human colorectal cancer cell lines, and PC-3 human prostate cancer at two concentrations of 100 μM and 10 μM were determined. The inhibition percentages were obtained through CCK-8 method. Detailed results are as follows:







TABLE 6







In vitro anti-proliferative effects of the


compounds on Hut-78 and PANC-1 cell strains










Hut-78 (inhibition %)
PANC-1 (inhibition %)
















Serial
Compound
100
SD 100
10
SD 10
100
SD 100
10
SD 10


number
I.D.
μM
μM
μM
μM
μM
μM
μM
μM



















Positive
MS-275
85.3
6.5
61.8
6.7
31.6
4.0
12.4
7.3


control


1
V-1
67.2
14.6
36.0
1.9
65.4
3.8
40.2
3.1


2
V-2
82.8
2.3
63.4
4.1
74.1
2.7
20.7
9.8


3
V-3
92.9
1.9
18.2
8.0
5.5
11.3
5.7
9.5


4
V-4
95.8
3.0
66.4
9.6
11.9
1.7
14.4
6.8


5
V-5
43.9
2.5
15.0
6.4
45.9
2.5
10.5
14.3


6
V-6
66.6
1.4
15.5
3.9
19.7
12.6
16.9
7.5


7
V-7
60.3
4.8
10.7
4.8
35.2
0.0
1.1
8.4


8
V-8
83.6
1.7
17.5
6.2
34.9
6.1
−1.8
3.5


9
V-9
94.0
1.9
10.8
1.4
26.4
1.2
22.3
6.9


10
V-10
47.5
2.1
8.1
4.0
19.0
1.5
13.0
4.7


11
V-11
84.6
3.8
28.5
1.6
21.1
6.1
24.0
3.6


12
V-12
62.5
1.7
62.5
9.5
21.9
7.5
15.8
5.1


13
V-13
54.0
7.6
19.8
2.0
36.8
9.1
26.0
9.2


14
V-14
91.1
2.4
22.0
5.8
15.7
5.3
−2.8
9.3


15
V-15
80.4
0.9
70.7
2.7
0.5
3.9
7.2
5.9


16
V-16
20.7
2.1
26.2
1.2
7.8
0.8
8.0
0.5


17
V-17
93.5
4.1
73.4
1.7
25.1
10.3
12.0
8.0


18
V-18
82.3
2.4
39.9
4.3
23.9
3.7
0.9
1.5


19
V-19
77.0
2.7
43.0
7.0
26.2
9.0
20.2
10.9


20
V-20
85.7
4.5
44.4
3.5
52.0
1.9
−1.7
5.0


21
V-21
75.6
1.0
65.2
4.7
33.3
1.9
12.5
2.1


22
V-22
91.8
3.9
42.3
3.9
39.4
4.2
12.3
5.8


23
V-23
93.1
2.3
59.9
3.8
4.0
2.8
9.2
4.2


24
V-24
72.9
5.8
15.5
1.8
22.1
9.1
17.5
3.6


25
V-25
60.0
2.1
18.1
1.8
39.5
0.5
20.8
1.4


26
V-26
86.9
1.2
79.6
2.4
40.8
6.8
5.1
9.5


27
V-27
89.3
3.1
69.2
0.8
69.5
5.9
44.4
1.2


28
V-29
94.0
0.3
79.4
0.8
18.4
5.3
0.9
8.9


29
V-31
95.8
4.7
28.2
2.9
50.6
0.4
20.8
1.0


30
V-43
89.6
1.6
75.7
4.1
35.9
1.7
3.1
1.1


31
V-46
93.4
3.1
16.4
2.8
70.4
4.1
8.1
1.0


32
V-47
88.3
2.5
9.9
2.3
43.0
3.8
2.8
3.9


33
V-48
87.4
5.3
75.4
3.6
51.8
6.9
−2.2
6.8
















TABLE 7







In vitro anti-proliferative effects of the compounds


on Jurkat E6-1 and K562 cell strains










Jurkat E6-1 (inhibition %)
K562 (inhibition %)
















Serial
Compound
100
SD 100
10
SD 10
100
SD 100
10
SD 10


number
I.D.
μM
μM
μM
μM
μM
μM:
μM
μM



















Positive
MS-275
96.1
0.8
89.5
1.5
74.6
2.1
66.2
1.5


control


1
V-1
79.3
0.7
48.5
0.7
30.8
5.4
22.4
1.6


2
V-2
85.9
0.3
58.5
2.1
64.4
3.7
21.0
8.0


3
V-3
96.0
0.8
27.1
2.4
85.1
1.6
51.0
4.0


4
V-4
23.7
6.2
5.4
5.5
38.1
6.9
−1.3
6.6


5
V-5
87.9
0.9
62.2
1.8
83.2
3.0
49.4
3.0


6
V-6
93.3
2.0
27.2
3.5
87.2
2.0
53.6
2.1


7
V-7
91.0
0.3
26.4
3.7
82.6
1.3
29.7
3.3


8
V-8
96.3
0.2
36.4
2.2
94.5
1.0
56.9
3.0


9
V-9
22.8
1.2
0.9
3.2
30.3
1.8
−2.8
7.2


10
V-10
72.8
4.3
25.3
7.3
62.1
1.5
45.0
2.7


11
V-11
26.3
3.5
18.6
1.7
32.3
0.2
20.4
6.8


12
V-12
87.4
2.3
25.0
7.9
69.8
2.8
49.3
2.2


13
V-13
77.8
2.4
19.1
2.7
65.1
0.7
25.0
1.8


14
V-14
96.5
0.2
23.8
4.3
88.7
1.4
34.0
8.4


15
V-15
13.9
4.2
33.7
3.2
11.9
8.6
27.2
0.8


16
V-16
22.1
3.0
37.2
6.3
29.7
2.0
42.8
2.3


17
V-17
80.2
1.5
20.3
1.9
72.4
2.3
33.6
4.2


18
V-18
95.7
0.2
76.6
1.8
87.5
2.5
58.5
7.1


19
V-19
80.9
2.0
58.3
2.2
85.8
1.7
54.3
2.6


20
V-20
89.4
1.6
84.8
1.5
92.9
1.6
64.3
4.9


21
V-21
89.7
0.4
49.3
2.9
85.2
2.0
52.2
2.5


22
V-22
88.2
1.3
83.1
1.7
83.4
3.1
60.9
4.0


23
V-23
52.7
3.5
4.7
2.3
61.2
1.4
12.8
2.3


24
V-24
91.4
2.3
30.7
3.7
75.3
2.8
−1.7
7.3


25
V-25
83.3
2.2
12.5
0.7
64.8
4.5
34.1
3.5


26
V-26
95.1
0.8
76.9
1.4
88.2
2.1
54.0
3.8


27
V-27
87.6
0.7
31.6
2.1
75.0
3.5
45.0
2.6


28
V-29
96.2
1.7
51.5
3.3
83.8
1.8
57.4
3.6


29
V-31
93.7
0.3
62.4
0.9
67.7
1.5
27.9
2.3


30
V-43
96.8
1.0
69.1
0.9
60.8
0.3
13.8
1.6


31
V-46
1.9
1.8
14.8
3.0
18.9
10.6
27.3
6.1


32
V-47
76.6
0.7
59.4
1.1
62.1
5.7
58.0
3.4


33
V-48
61.9
2.9
9.7
2.9
57.2
2.3
20.0
6.6
















TABLE 8







In vitro anti-proliferative effects of the compounds


on A549 and MDA-MB-435s cell strains










A549 (inhibition %)
435s (inhibition %)
















Serial
Compound
100
SD 100
10
SD 10
100
SD 100
10
SD 10


number
I.D.
μM
μM
μM
μM
μM
μM
μM
μM



















Positive
MS-275
92.3
0.3
58.9
11.2
59.3
5.3
2.7
6.0


control


1
V-1
89.7
0.8
50.6
0.9
87.5
3.0
26.7
5.4


2
V-2
84.8
1.1
65.6
1.6
86.9
1.8
35.8
1.9


3
V-3
72.3
6.4
−7.8
1.2
85.5
0.8
4.5
2.6


4
V-4
−19.4
38.8
−43.9
50.0
−10.4
4.7
−20.7
7.6


5
V-5
−13.1
14.8
−44.3
44.3
84.1
8.1
−14.3
5.3


6
V-6
45.7
2.8
−16.9
1.9
79.1
1.8
8.0
5.1


7
V-7
24.9
14.0
−7.4
13.4
85.4
9.2
−16.5
2.8


8
V-8
38.0
60.8
−5.9
2.7
94.5
0.5
14.2
4.9


9
V-9
42.3
3.2
24.6
10.8
11.8
6.0
−11.9
2.8


10
V-10
40.1
0.3
−4.4
0.6
82.9
1.4
9.4
10.1


11
V-11
12.9
6.1
15.3
8.5
42.4
1.2
30.6
7.2


12
V-12
55.1
1.5
−9.0
3.7
77.2
4.5
5.7
11.5


13
V-13
57.1
10.3
18.3
3.0
89.1
2.0
27.5
2.9


14
V-14
72.2
1.5
−17.6
1.8
63.9
1.4
19.5
3.1


15
V-15
3.5
5.0
4.7
5.0
21.0
4.1
21.6
2.1


16
V-16
65.7
0.2
48.7
10.9
50.4
3.2
49.8
2.6


17
V-17
67.9
3.0
29.8
5.3
73.3
3.7
32.5
8.1


18
V-18
79.1
0.5
9.5
1.5
81.4
2.5
22.7
5.6


19
V-19
37.3
4.1
6.3
2.9
77.0
7.7
33.0
5.5


20
V-20
41.3
3.3
0.0
5.3
57.8
4.8
17.0
7.6


21
V-21
96.4
0.4
17.1
3.6
88.8
11.7
25.2
5.9


22
V-22
69.9
1.3
21.8
1.6
81.4
6.6
18.0
4.6


23
V-23
6.2
6.0
−7.4
11.4
42.9
6.0
21.5
4.3


24
V-24
20.8
5.1
7.3
2.0
24.5
4.7
−10.8
11.5


25
V-25
12.0
3.9
2.4
8.0
61.2
2.2
30.8
6.5


26
V-26
63.7
1.5
4.2
5.7
73.6
5.9
16.6
3.2


27
V-27
97.7
5.9
82.8
1.7
76.3
2.2
28.5
5.8


28
V-29
69.8
1.2
6.3
0.9
78.5
1.7
10.1
6.3


29
V-31
88.8
1.0
56.3
0.7
89.2
1.0
24.2
6.2


30
V-43
85.5
0.3
41.2
1.1
86.4
1.9
18.8
6.3


31
V-46
4.1
4.6
7.7
2.2
4.1
5.8
16.4
4.1


32
V-47
8.0
0.4
9.4
2.0
29.2
3.5
21.8
5.8


33
V-48
9.8
7.6
3.9
7.0
26.6
4.4
10.0
11.1
















TABLE 9







In vitro anti-proliferative effects of the compounds or Hep3B and PC-3 cell strains










Hep3B (inhibition %)
PC-3 (inhibition %)
















Serial
Compound
100
SD 100
10
SD 10
100
SD 100
10
SD 10


number
I.D.
μM
μM
μM
μM
μM
μM
μM
μM



















Positive
MS-275
52.1
0.1
10.8
7.5
71.5
0.4
12.5
3.2


control


1
V-1
37.4
17.5
2.6
8.0
91.5
0.5
79.5
0.4


2
V-2
53.6
10.4
31.2
10.4
92.4
0.8
90.3
1.2


3
V-3
59.2
3.5
−12.3
6.9
36.9
2.7
0.6
8.4


4
V-4
−12.1
2.3
−10.2
6.4
15.9
8.2
5.2
16.1


5
V-5
66.6
4.2
7.3
11.3
66.7
5.8
0.0
6.6


6
V-6
57.5
10.7
−7.0
24.4
56.0
12.1
23.7
4.1


7
V-7
53.2
15.7
8.1
4.6
49.8
6.9
8.1
12.4


8
V-8
90.4
2.6
5.0
9.9
89.3
3.2
29.7
13.2


9
V-9
26.2
7.6
27.0
11.2
19.3
5.5
5.1
8.5


10
V-10
31.3
0.2
3.7
9.8
57.4
6.0
13.7
11.8


11
V-11
43.0
2.5
22.3
17.7
18.8
2.1
21.9
7.5


12
V-12
67.1
10.0
4.7
26.2
61.3
7.5
25.5
22.1


13
V-13
69.8
6.4
21.5
6.0
48.5
2.5
−1.9
1.3


14
V-14
79.3
2.3
7.2
11.1
84.4
2.5
22.9
8.5


15
V-15
11.2
11.6
16.3
7.5
8.6
4.6
10.9
4.7


16
V-16
13.5
8.5
24.8
2.0
3.4
1.4
5.1
11.2


17
V-17
45.7
0.4
18.4
9.3
67.1
4.7
41.8
7.1


18
V-18
75.1
2.4
13.8
5.2
72.2
3.9
45.2
1.9


19
V-19
49.9
6.9
25.4
9.5
61.0
2.9
50.2
2.0


20
V-20
60.0
6.3
23.5
5.2
75.5
0.5
48.1
2.6


21
V-21
68.1
4.9
11.0
9.4
64.2
2.8
40.1
3.6


22
V-22
69.2
2.8
38.3
13.8
69.0
1.3
44.6
3.9


23
V-23
28.1
10.0
1.0
2.8
40.2
14.0
7.0
1.7


24
V-24
69.5
0.7
14.3
8.5
63.7
2.3
13.1
2.2


25
V-25
40.6
2.8
11.3
8.1
22.1
4.7
−9.4
11.8


26
V-26
63.5
3.0
11.7
7.2
52.6
0.2
8.7
7.0


27
V-27
68.3
0.8
−12.3
5.6
59.9
3.2
43.8
5.8


28
V-29
60.5
4.0
22.5
6.6
94.5
0.5
88.0
0.8


29
V-31
51.7
26.7
−5.0
0.4
38.8
9.1
6.3
7.8


30
V-43
58.8
1.5
21.2
3.1
89.4
0.7
81.4
0.3


31
V-46
−5.0
15.4
17.5
24.0
−2.4
3.0
−1.7
1.5


32
V-47
19.2
15.2
11.2
24.7
12.8
8.6
7.2
9.4


33
V-48
20.5
12.2
−14.0
9.7
14.8
7.9
−16.4
7.2
















TABLE 10







In vitro anti-proliferative effects of the compounds on Colo320


cell strain










Compound
Colo320 (inhibition %)












Serial number
I.D.
100 μM
SD 100 μM
10 μM
SD 10 μM















Positive control
MS-275
61.6
0.5
18.0
4.6


1
V-1
78.3
1.2
33.7
6.4


2
V-2
92.9
12.4
39.6
1.1


3
V-3
47.2
3.6
−7.1
5.9


4
V-4
16.8
12.2
7.1
5.0


5
V-5
45.3
2.1
13.0
4.4


6
V-6
59.2
4.1
−5.5
4.2


7
V-7
48.5
3.2
8.9
5.4


8
V-8
86.4
0.2
−1.8
2.8


9
V-9
4.2
6.6
4.4
4.0


10
V-10
23.3
6.0
6.4
6.3


11
V-11
4.1
4.6
2.6
4.2


12
V-12
46.1
2.7
2.4
3.7


13
V-13
34.3
4.1
0.9
4.0


14
V-14
82.7
18.7
−14.3
4.8


15
V-15
3.9
2.5
15.3
5.4


16
V-16
−17.1
3.2
−2.3
7.9


17
V-17
28.9
4.0
4.9
7.9


18
V-18
56.3
14.5
7.7
4.0


19
V-19
40.1
4.6
12.9
6.1


20
V-20
58.8
19.4
6.5
2.7


21
V-21
45.9
3.6
9.5
7.8


22
V-22
40.8
15.8
5.4
3.8


23
V-23
5.9
4.6
7.3
7.5


24
V-24
16.5
8.6
−1.7
5.1


25
V-25
14.1
1.0
7.9
4.2


26
V-26
44.4
11.2
−0.2
6.0


27
V-27
82.3
3.9
60.0
3.9


28
V-29
35.5
4.1
−7.2
1.0


29
V-31
77.0
2.8
76.3
20.9


30
V-43
59.4
2.0
19.1
2.4


31
V-46
−9.0
7.5
13.7
3.8


32
V-47
6.0
2.8
11.0
4.6


33
V-48
17.9
1.6
2.9
4.1
















TABLE 11







Determination of the IC50 values for the in vitro anti-proliferative


effects of the compounds on tumor cell strains









IC50 (μM)














Compound
PC-3
A549
Colo320
Hep3B
Hut78
K562
Jurkat E6-1

















MS-275
0.5020
2.278
0.5222
6.816
0.5281
4.663
0.5614


V-9
12.17
29.92
88.405
52.172
0.2311
19.851
12.353


V-14
3.568
5.089
26.997
15.997
0.0558
2.811
1.392


V-27

3.136

1.523
0.3557
0.4369
0.4578









EXAMPLE 52
Test of Maximum Tolerance Dose as a Measure of the Compounds' Toxicity Through Intragastrical Administration
Forty ICR mice, half female and half male, weighing 8 ̃20 g were divided into four groups, 10 mice in each group. After the mice were fasted for 6 h, the compound to be tested was administrated intragastrically to each group at a volume of 0.3 ml/10 g by using a sterile plastic syringe. General physical signs and the deaths of the animals were record at 1, 2 and 4 h after the administration. The animals were then observed continuously for 14 days and their weights, physical signs and deaths were observed and recorded every day. Dead animals were dissected to see if there was any visible pathological change in the animal's viscera and pathological examination was performed on suspicious tissues and organs. A part of the experimental results is as follows.
The maximum tolerance doses of Compounds V-1, V-4, V-6, V-9, V-13, V-17, V-20, V-25, V-29, V-43, and V-47 when administrated intragastrically are over 5000 mg/kg in mice, and the same of Compounds V-2, V-5, V-11, V-14, V-18, V-22, V-24, V-27 and V-46 are over 2000 mg/kg.
EXAMPLE 53







TABLE 12







Effects of the compounds on hERG potassium channel










Half inhibition




concentration for the effect




on hERG potassium current,
Maximum inhibition


Compound
IC50 (μM)
percentage at 10 μM (%)





V-9
>10
21.5 ± 0.4


V-27
>10
29.9 ± 6.7









EXAMPLE 54







TABLE 13







Preliminary pharmacokinetic results of the compounds











Intravenous half-life in
Oral half-life
Oral


Compound
hours (rat, 2 mg/kg, i.v.)
in hours
bioavailability %













V-9
1.27
4.53
18.99


V-27
0.95
3.37
28.6









EXAMPLE 55
In Vivo Test of Compounds for Human Tumors Transplanted in Nude Mice
The inhibitory effect of Compound V-9 (50 mg/kg) on the growth of human PC-3 tumors transplanted in nude mice was investigated in vivo using MS-275 as the positive control. The inhibitory effect of Compound V-27 (50 mg/kg) on the growth of human A549 tumors transplanted in nude mice was investigated in vivo using MS-275 as the positive control. The experimental results are as follows.







TABLE 14







In vivo test of compounds for human tumors transplanted in nude mice









In vivo test for human tumors transplanted in



nude mice (50 mg/kg)



inhibition % (8 mice in each group)









Compound
PC-3 (human prostate cancer)
A549 (lung cancer)





MS-275
89.60% (4 deaths)
79.41% (3 deaths)


V-9
36.97% (no death)



V-27

61.83% (no death)









EXAMPLE 56
Tablet

















The compound of any one of Examples 1-48
10
mg



Sucrose
150
mg



Corn starch
38
mg



Calcium stearate
2
mg










Preparation method: The active ingredient, sucrose and corn starch can be mixed, wetted by adding water and stirred thoroughly to obtain a homogenous mixture which can be dried, grounded and sieved. Then calcium stearate can be added and mixed homogenously before pressing to form a tablet. Each tablet weighs 200 mg, containing 10 mg active ingredient.
EXAMPLE 57
Injection
















The compound of any one of Examples 1-48
20 mg



Water for injection
80 mg










Preparation method: The active ingredient can be dissolved in water for injection, mixed homogenously and filtered. The resultant solution can be dispensed into ampoules under aseptic conditions, 10 mg in each ampoule with 2 mg active ingredient therein.

## Claims

1. A compound selected from the group consisting of:
V-1 N-(2-aminophenyl)-4-(quinazoline-4-amino)benzamide,
V-2 N-(2-amino-4-pyridyl)-4-(quinazoline-4-amino)benzamide,
V-3 N-(2-amino-5-fluorophenyl)-4-(quinazoline-4-amino)benzamide,
V-4 N-(2-amino-4-pyridyl)-4-(6,7-dimethoxyquinazoline-4-amino)benzamide,
V-5 N-(2-aminophenyl)-4-(6-methoxyquinazoline-4-amino)benzamide,
V-6 N-(2-amino-5-fluorophenyl)-4-(6-methoxyquinazoline-4-amino)benzamide,
V-7 N-(2-aminophenyl) 4-(5-methoxyquinazoline-4-amino)benzamide,
V-8 N-(2-amino-4-pyridyl)-4-(5-methoxyquinazoline-4-amino)benzamide,
V-9 N-(2-aminophenyl)-4-(8-methoxyquinazoline-4-amino)benzamide,
V-10 N-(2-amino-5-fluorophenyl)-4-(8-methoxyquinazoline-4-amino)benzamide,
V-11 N-(2-aminophenyl)-4-(6-nitroquinazoline-4-amino)benzamide,
V-12 N-(2-aminophenyl)-4-(6-fluoroquinazoline-4-amino)benzamide,
V-13 N-(2-aminophenyl)-4-(7-fluoroquinazoline-4-amino)benzamide,
V-14 N-(2-amino-5-fluorophenyl)-4-(8-fluoroquinazoline-4-amino)benzamide,
V-15 N-(2-aminophenyl)-4-(6,7-dimethoxyethoxyquinazoline-4-amino)benzamide,
V-16 N-(2-amino-4-pyridyl)-4-(6,7-dimethoxyethoxyquinazoline-4-amino)benzamide,
V-17 N-(2-aminophenyl)-4-[7-methoxy-6-(3-morpholinylpropoxy)quinazoline-4-amino]benzamide,
V-18 N-(2-amino-5-fluorophenyl)-4-[7-methoxy-6-(3-morpholinyl propoxy)quinazoline-4-amino]benzamide,
V-19 N-(2-aminophenyl)-4-[6-(5-((2-(methylsulfonyl)ethylamino)methyl)furyl)quinazoline-4-amino]benzamide,
V-20 N-(2-amino-5-fluorophenyl)-4-[6-(5-((2-(methylsulfonyl)ethylamino)methyl)furyl)quinazoline-4-amino]benzamide,
V-21 N-(2-aminophenyl)-4-(6-acetamidoquinazoline-4-amino)benzamide,
V-22 N-(2-aminophenyl)-4-(6-methoxycarbonylmethylquinazoline-4-amino)benzamide,
V-23 N-[2-amino-5-(2-thienyl)phenyl]-4-(6,7-dimethoxyquinazoline-4-amino)benzamide,
V-24 N-[2-amino-5-(phenyl)phenyl]-4-(6,7-dimethoxyquinazoline-4-amino)benzamide,
V-25 N-[2-amino-5-(2-furyl)phenyl]-4-(6,7-dimethoxyquinazoline-4-amino)benzamide,
V-26 N-(2-amino-4-pyridyl)-4-[(quinazoline-4-amino)methyl]benzamide,
V-27 N-(2-aminophenyl)-4-[(quinazoline-4-amino)methyl]benzamide,
V-28 N-[2-amino-5-(2-thienyl)phenyl]-4-[(quinazoline-4-amino)methyl]benzamide,
V-29 N-(2-amino-5-fluorophenyl)-4-[(quinazoline-4-amino)methyl]benzamide,
V-30 N-(2-amino-4-pyridyl)-4-[(6,7-dimethoxyquinazoline-4-amino)methyl]benzamide,
V-31 N-[2-amino-5-(2-thienyl)phenyl]-4-[(6,7-dimethoxyquinazoline-4-amino)methyl]benzamide,
V-32 N-(2-aminophenyl)-4-[(7-methoxyquinazoline-4-amino)methyl]benzamide,
V-33 N-(2-aminophenyl)-4-[(6-methoxyquinazoline-4-amino)methyl]benzamide,
V-34 N-(2-aminophenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide,
V-35 N-(2-amino-5-fluorophenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide,
V-36 N-(2-amino-5-(phenyl)phenyl)-4-[(8-methoxyquinazoline-4-amino)methyl]benzamide,
V-37 N-(2-aminophenyl)-4-[(6-nitroquinazoline-4-amino)methyl]benzamide,
V-38 N-(2-aminophenyl)-4-[(6,7-dimethoxyethoxyquinazoline-4-amino)methyl]benzamide,
V-39 N-(2-amino-4-pyridyl)-4-[(6,7-dimethoxyethoxyquinazoline-4-amino)methyl]benzamide,
V-40 N-(2-amino-5-fluorophenyl)-4-[(6,7-dimethoxyethoxyquinazoline-4-amino)methyl]benzamide,
V-41 N-(2-aminophenyl)-4-[(7-methoxy-6-(3-morpholinylpropoxy)quinazoline-4-amino)methyl]benzamide,
V-42 N-(2-amino-4-pyridyl)-4-[(7-methoxy-6-(3-morpholinylpropoxy)quinazoline-4-amino)methyl]benzamide,
V-43 N-(2-aminophenyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide,
V-44 N-(2-amino-4-pyridyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide,
V-45 N-(2-amino-5-(2-furyl)phenyl)-4-[(8-fluoroquinazoline-4-amino)methyl]benzamide,
V-46 N-(2-aminophenyl)-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide,
V-47 N-(2-amino-4-pyridyl)-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide, or
V-48 N-[2-amino-5-(2-furyl)phenyl]-4-[(6-acetamidoquinazoline-4-amino)methyl]benzamide.

2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or a salt thereof, and a pharmaceutically acceptable carrier.